BoLA-DR peptide binding pockets are fundamental for foot-and-mouth disease virus vaccine design in cattle

Vaccine

Volumn 28, Issue 1, 2009, Pages 28-37

  Baxter, R ^a   Craigmile, S C ^a   Haley, C ^a,b   Douglas, A J ^c   Williams, J L ^d   Glass, E J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c AGRI FOOD AND BIOSCIENCES INSTITUTE   (United Kingdom)

^d PARCO TECNOLOGICO PADANO   (Italy)

Author keywords

BoLA DRB3; FMDV; Foot and mouth disease; Peptide binding pockets; Vaccine

Indexed keywords

ARGININE; FOOT AND MOUTH DISEASE VACCINE; GLUTAMIC ACID; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; VIRUS PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; BOLA DRB3 GENE; CATTLE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE; GENE LOCUS; GENE SEQUENCE; GENETIC POLYMORPHISM; HISTOCOMPATIBILITY; IMMUNE RESPONSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN BINDING; T LYMPHOCYTE;

ALLELES; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; AREA UNDER CURVE; BINDING SITES; CAPSID PROTEINS; CATTLE; EPITOPES; FEMALE; FOOT-AND-MOUTH DISEASE; GENE FREQUENCY; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNOGLOBULIN G; PEPTIDE FRAGMENTS; POLYMORPHISM, GENETIC; VIRAL VACCINES;

EID: 70649084895     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.131     Document Type: Article

References (53)

1. Sobrino F., Saiz M., Jimenez-Clavero M.A., Nunez J.I., and Rosas M.F. Foot-and-mouth disease virus: a long known virus, but a current threat. Veterinary Research 32 January (1) (2001) 1-30
2. Anonymous. Official Journal of the European Union 46 (2003) L306 [Council Directive 2003/85/EC]
3. The Royal Society. Infectious diseases in livestock. Chapter 5. http://www.royalsoc.ac.uk/inquiry/, Surveillance, biosecurity and livestock management (2002)
4. Grubman M.J., and Baxt B. Foot-and-mouth disease. Clinical Microbiology Reviews 17 April (2) (2004) 465-493
5. Collen T., Dimarchi R., and Doel T.R. A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. Journal of Immunology 146 January (2) (1991) 749-755
6. Taboga O., Tami C., Carrillo E., Nunez J.I., Rodriguez A., Saiz J.C., et al. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. Journal of Virology 71 April (4) (1997) 2606-2614
7. Wang C.Y., Chang T.Y., Walfield A.M., Ye J., Shen M., Chen S.P., et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20 June (19-20) (2002) 2603-2610
8. Sadir A.M., Zamorano P.I., Romera A., Wigdorovitz A., Smitsaart E., Marangunich L., et al. Improvement of the immune response to foot and mouth disease virus vaccine in calves by using Avridine as adjuvant. Veterinary Immunology and Immunopathology 69 July (1) (1999) 11-22
9. Dimarchi R., Brooke G., Gale C., Cracknell V., Doel T., and Mowat N. Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 232 May (4750) (1986) 639-641
10. Cubillos C., de la Torre B.G., Jakab A., Clementi G., Borras E., Barcena J., et al. Enhanced mucosal immunoglobulin a response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. Journal of Virology 82 July (14) (2008) 7223-7230
11. Greenwood D.L.V., Dynon K., Kalkanidis M., Xiang S., Plebanski M., and Scheerlinck J.P.Y. Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads. Vaccine 26 May (22) (2008) 2706-2713
12. Poland G.A., Ovsyannikova N.G., and Jacobson R.M. Vaccine immunogenetics: bedside to bench to population. Vaccine 26 November (49) (2008) 6183-6188
13. Glass E.J. Genetic variation and response to vaccines. Animal Health Research Reviews 5 2 (2004) 197-208
14. Sette A., and Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Current Opinion in Immunology 15 August (4) (2003) 461-470
15. Lewin H.A., Russell G.C., and Glass E.J. Comparative organization and function of the major histocompatibility complex of domesticated cattle. Immunological Reviews 167 February (1999) 145-158
16. Ballingall K.T., Luyai A., Rowlands G.J., Sales J., Musoke A.J., Morzaria S.P., et al. Bovine leukocyte antigen major histocompatibility complex class II DRM3*2703 and DRB3*1501 alleles are associated with variation in levels of protection against Theileria parva challenge following immunization with the sporozoite p67 antigen. Infection and Immunity 72 May (5) (2004) 2738-2741
17. Xu A.L., Vaneijk M.J.T., Park C., and Lewin H.A. Polymorphism in BoLA-DRB3 exon-2 correlates with resistance to persistent lymphocytosis caused by Bovine Leukemia-Virus. Journal of Immunology 151 December (12) (1993) 6977-6985
18. Alizadeh Z., Karrow N., and Mallard B.A. Biological effect of varying peptide binding affinity to the BoLA-DRB3*2703 allele. Genetics Selection Evolution 35 (2003) S51-S65
19. Juliarena M.A., Poli M., Sala L., Ceriani C., Gutierrez S., Dolcini G., et al. Association of BLV infection profiles with alleles of the BoLA-DRB3.2 gene. Animal Genetics 39 August (4) (2008) 432-438
20. Dietz A.B., Detilleux J.C., Freeman A.E., Kelley D.H., Stabel J.R., and Kehrli M.E. Genetic association of bovine lymphocyte antigen DRB3 alleles with immunological traits of Holstein cattle. Journal of Dairy Science 80 February (2) (1997) 400-405
21. Lie O., Solbu H., Larsen H.J., and Spooner R.L. Possible association of antibody-responses to human-serum albumin and (T,G)-A-l with the bovine major histocompatibility complex (BoLA). Veterinary Immunology and Immunopathology 11 April (4) (1986) 333-350
22. Newman M.J., Truax R.E., French D.D., Dietrich M.A., Franke D., and Stear M.J. Evidence for genetic control of vaccine-induced antibody responses in cattle. Veterinary Immunology and Immunopathology 50 March (1-2) (1996) 43-54
23. Glass E.J., and Millar P. Induction of effective cross-reactive immunity by FMDV peptides is critically dependent upon specific MHC-peptide-T cell-interactions. Immunology 82 May (1) (1994) 1-8
24. Garcia-Briones M.M., Russell G.C., Oliver R.A., Tami C., Taboga O., Carrillo E., et al. Association of bovine DRB3 alleles with immune response to FMDV peptides and protection against viral challenge. Vaccine 19 December (9-10) (2000) 1167-1171
25. Baxter R., Hastings N., Law A., and Glass E.J. A rapid and robust sequence-based genotyping method for BoLA-DRB3 alleles in large numbers of heterozygous cattle. Animal Genetics 39 October (5) (2008) 561-563
26. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L., et al. Crystal-structure of the human class-II MHC protein HLA-DR1 complexed with an influenza-virus peptide. Nature 368 6468 (1994) 215-221
27. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L., et al. 3-Dimensional structure of the human class-II histocompatibility antigen HLA-DR1. Nature 364 6432 (1993) 33-39
28. Zavala-Ruiz Z., Strug I., Anderson M.W., Gorski J., and Stern L.J. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Chemistry & Biology 11 October (10) (2004) 1395-1402
29. Fu X.T., Bono C.P., Woulfe S.L., Swearingen C., Summers N.L., Sinigaglia F., et al. Pocket 4 of the HLA-DR (alpha, beta 1*0401) molecule is a major determinant of T cells recognition of peptide. Journal of Experimental Medicine 181 March (3) (1995) 915-926
30. Sharif S., Mallard B.A., and Sargeant J.M. Presence of glutamine at position 74 of pocket 4 in the BoLA-DR antigen binding groove is associated with occurrence of clinical mastitis caused by Staphylococcus species. Veterinary Immunology and Immunopathology 76 October (3-4) (2000) 231-238
31. Sitte K., Brinkworth R., East I.J., and Jazwinska E.C. A single amino acid deletion in the antigen binding site of BoLA-DRB3 is predicted to affect peptide binding. Veterinary Immunology and Immunopathology 85 March (3-4) (2002) 129-135
32. Zerva L., Cizman B., Mehra N.K., Alahari S.K., Murali R., Zmijewski C.M., et al. Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy. Journal of Experimental Medicine 183 March (3) (1996) 829-836
33. Maillard J.C., Martinez D., and Bensaid A. An amino acid sequence coded by the exon 2 of the BoLA DRB3 gene associated with a BoLA class I specificity constitutes a likely genetic marker of resistance to dermatophilosis in Brahman zebu cattle of Martinique (FWI). Vector-Borne Pathogens: International Trade and Tropical Animal Diseases 791 (1996) 185-197
34. Glass E.J., Oliver R.A., Collen T., Doel T.R., Dimarchi R., and Spooner R.L. MHC Class-II restricted recognition of FMDV peptides by bovine T-cells. Immunology 74 4 (1991) 594-599
35. Hall T.A. BioEdit: a user friendly biological sequence editor and analysis program for window 95/98/NT. Nucleic Acids Symposium Series 41 (1999) 95-98
36. Sharif S., Mallard B.A., and Wilkie B.N. Characterization of naturally processed and presented peptides associated with bovine major histocompatibility complex (BoLA) class II DR molecules. Animal Genetics 34 April (2) (2003) 116-123
37. Patterson H., and Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrika 58 3 (1971) 545
38. Elsik C.G., Tellam R.L., Worley K.C., and The Bovine Genome Sequencing and Analysis Consortium. The genome sequence of taurine cattle: a window to ruminant biology and evolution. Science 324 April (2009) 522-528
39. Glass E.J., Oliver R.A., and Russell G.C. Duplicated DQ haplotypes increase the complexity of restriction element usage in cattle. Journal of Immunology 165 July (1) (2000) 134-138
40. Gerner W., Hammer S.E., Wiesmuller K.H., and Saalmuller A. Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virus-derived bovine T-cell epitopes. Journal of Virology 83 May (9) (2009) 4039-4050
41. Fraser D.C., Craigmile S., Campbell J.D.M., Oliver R.A., Brown D.J., Russell G.C., et al. Functional expression of a cattle MHC class II DR-like antigen on mouse L cells. Immunogenetics 43 5 (1996) 296-303
42. Glass E.J., and Millar P. Bovine T-cells preferentially recognize nonviral spacer epitopes in a putative FMDV vaccinal peptide. Vaccine 13 February (2) (1995) 225-229
43. Glass E.J., Oliver R.A., and Spooner R.L. Bovine T-cells recognize antigen in association with MHC class-II haplotypes defined by one-dimensional isoelectric-focusing. Immunology 72 March (3) (1991) 380-385
44. Haghparast A., Wauben M.H.M., Grosfeld-Stulemeyer M.C., van Kooten P., and Hensen E.J. Selection of T-cell epitopes from foot-and-mouth disease virus reflects the binding affinity to different cattle MHC class II molecules. Immunogenetics 51 July (8) (2000) 733-742
45. Vanlierop M.J.C., Nilsson P.R., Wagenaar J.P.A., Vannoort J.M., Campbell J.D.M., Glass E.J., et al. The influence of MHC polymorphism on the selection of T-cell determinants of FMDV in cattle. Immunology 84 January (1) (1995) 79-85
46. Goris N., Willems T., Diev V.I., Merkelbach-Peters P., Vanbinst T., Van der Stede Y., et al. Indirect foot-and-mouth disease vaccine potency testing based on a serological alternative. Vaccine 26 July (31) (2008) 3870-3879
47. Capozzo A.V.E., Periolo O.H., Robiolo B., Seki C., LaTorre J.L., and Grigera P.R. Total and isotype humoral responses in cattle vaccinated with foot and mouth disease virus (FMDV) immunogen produced either in bovine tongue tissue or in BHK-21 cell suspension cultures. Vaccine 15 April (6-7) (1997) 624-630
48. Parida S., Oh Y., Reid S.M., Cox S.J., Statham R.J., Mahapatra M., et al. Interferon-gamma production in vitro from whole blood of foot-and-mouth disease virus (FMDV) vaccinated and infected cattle after incubation with inactivated FMDV. Vaccine 24 February (7) (2006) 964-969
49. Cardenas C., Ortiz M., Balbin A., Villaveces J.L., and Patarroyo M.E. Allele effects in MHC-peptide interactions: a theoretical analysis of HLA-DR beta 1*0101-HA and HLA-DR beta 1*0401-HA complexes. Biochemical and Biophysical Research Communications 330 May (4) (2005) 1162-1167
50. Takeshima S., Sarai Y., Saitou N., and Aida Y. MHC class II DR classification based in antigen-binding groove natural selection. Biochemical and Biophysical Research Communications 385 July (2) (2009) 137-142
51. Penn D.J., Damjanovich K., and Potts W.K. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proceedings of the National Academy of Sciences of the United States of America 99 August (17) (2002) 11260-11264
52. Thursz M.R., Thomas H.C., Greenwood B.M., and Hill A.V.S. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nature Genetics 17 September (1) (1997) 11-12
53. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 March (5408) (1999) 1748-1752